Evaluation of Doxil as First-Line Therapy of Advanced or Recurrent Endometrial Carcinoma
OBJECTIVES:
- Determine the antitumor activity and safety of doxorubicin HCl liposome in patients
with advanced or recurrent endometrial cancer.
- Determine the response rate, response duration, and overall survival of these patients
treated with this regimen.
OUTLINE: Patients receive doxorubicin HCl liposome IV over 1 hour. Courses repeat every 4
weeks in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months for 2 years and then every 6 months for 3 years.
PROJECTED ACCRUAL: A total of 19-51 patients will be accrued for this study.
Interventional
Primary Purpose: Treatment
Howard D. Homesley, MD
Study Chair
Gynecologic Oncology Network
United States: Federal Government
CDR0000067891
NCT00005861
May 2000
Name | Location |
---|---|
Chao Family Comprehensive Cancer Center | Orange, California 92868 |
Indiana University Cancer Center | Indianapolis, Indiana 46202-5265 |
University of Mississippi Medical Center | Jackson, Mississippi 39216-4505 |
Washington University School of Medicine | Saint Louis, Missouri 63110 |
Duke Comprehensive Cancer Center | Durham, North Carolina 27710 |
Arthur G. James Cancer Hospital - Ohio State University | Columbus, Ohio 43210 |
New England Medical Center Hospital | Boston, Massachusetts 02111 |
Comprehensive Cancer Center at Wake Forest University | Winston-Salem, North Carolina 27157-1082 |
Brookview Research, Inc. | Nashville, Tennessee 37203 |
Holden Comprehensive Cancer Center | Iowa City, Iowa 52242-1009 |